SLS — Sellas Life Sciences Balance Sheet
0.000.00%
- $64.11m
- $45.69m
Annual balance sheet for Sellas Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 7.28 | 35.3 | 21.4 | 17.1 | 2.53 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.308 | 1.13 | 0 | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 8.24 | 36.9 | 23 | 17.8 | 3.17 |
Net Property, Plant And Equipment | 0.217 | 0.896 | 0.723 | 0.874 | 0.858 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 16.6 | 46 | 26.3 | 20.9 | 6.22 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.29 | 12.3 | 4.98 | 15.5 | 13.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.5 | 18.1 | 5.93 | 16.1 | 14.2 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 6.09 | 28 | 20.3 | 4.85 | -7.98 |
Total Liabilities & Shareholders' Equity | 16.6 | 46 | 26.3 | 20.9 | 6.22 |
Total Common Shares Outstanding |